New Lung Cancer Combination Therapy Improves Outcomes
Patients with MET-driven lung cancer may see improved survival with a new two-drug regimen now under regulatory review.
Updated on Oct. 25, 2026 in Cancer
New trial results suggest that combining the drugs osimertinib and savolitinib may improve outcomes for patients with specific forms of advanced lung cancer. This combination treatment is aimed at individuals whose disease has progressed despite prior treatment with osimertinib.
Why it matters
For patients with MET-driven non-small cell lung cancer, this combination therapy offers a potential new standard of care after initial treatments fail. The findings provide a new therapeutic path for those who have exhausted standard options, though the regimen is specific to certain tumor mutations.
In a Phase 3 trial of 338 patients, the combination of osimertinib and savolitinib yielded a median progression-free survival of 7.6 months, compared to 5.4 months for chemotherapy. Researchers reported a 32% reduction in the risk of death, though the study is currently under regulatory review.
The players
ESMO Congress
An international medical oncology society that hosts annual meetings to present major cancer research developments.
FDA
The United States federal agency responsible for evaluating the safety and efficacy of new drug applications.
The details
The treatment works by targeting MET overexpression or amplification, a genetic pathway that often allows lung tumors to bypass the effects of earlier therapies. Patients in the trial were assigned to receive 80 mg of osimertinib once daily combined with 300 mg of savolitinib twice daily. This dual-action approach aims to block the signaling proteins that drive tumor growth in EGFR-mutated non-small cell lung cancer.
Timeline
July 6, 2026: Data cutoff for the SAFFRON trial analysis.
August 2026: Topline results confirmed primary endpoints were met.
September 2026: A new drug application was submitted to the FDA.
October 23-27, 2026: Results were presented at the ESMO Congress.
Health Landscape
The SAFFRON trial represents a shift in addressing drug resistance in lung cancer by moving toward combination therapies. It builds on the standard use of targeted inhibitors by specifically addressing the secondary mutations that arise during disease progression.
Patients with advanced non-small cell lung cancer who have experienced disease progression should talk to their oncologist about whether they have MET amplification. This development is relevant for those currently discussing potential treatment changes with their clinical team.
The takeaway
This combination therapy offers a potential survival benefit for those facing treatment-resistant lung cancer. Patients should discuss their tumor's genetic profile with their physician to understand if targeted therapies like these are appropriate for their specific case.
Further reading
For more on evolving research, visit our Cancer section.
